Top

Published in:

01-02-2020 | Insulins | Original Article

Circulatory miRNA biomarkers of metabolic syndrome

Authors: F. Ramzan, R. F. D’Souza, B. R. Durainayagam, A. M. Milan, J. F. Markworth, V. Miranda-Soberanis, I. R. Sequeira, N. C. Roy, S. D. Poppitt, C. J. Mitchell, D. Cameron-Smith

Published in: Acta Diabetologica | Issue 2/2020

Abstract

Aims

Circulatory microRNAs (c-miRNAs) exert important roles in the molecular dysregulation of cardio-metabolic diseases. However, little is known whether dysregulated miRNA expression occurs when risk factors are elevated, as in the metabolic syndrome (MetS). This study quantified c-miRNA expression in individuals with MetS compared to healthy, further examining the relationship of gene pathways with the underlying pathogenesis.

Methods

Expression of 26 miRNAs was quantified in plasma from 40 women (20 healthy and 20 MetS) and 39 men (20 healthy and 19 MetS) by qPCR. In silico analysis was performed to investigate biological effects of the dysregulated miRNAs. Dysregulated miRNA expression was further validated in an independent cohort of 20 women (10 healthy and 10 MetS).

Results

Regression model adjusted for age and sex identified miR-15a-5p, miR-17-5p, miR-370-3p and miR-375 as important predictors of MetS presence. Analysis of predictive miRNAs in the validation cohort strengthened the relationship with miR-15a-5p and miR-17-5p expression. These miRNAs share genes involved in the regulation of metabolic pathways including insulin, wnt, fatty acid metabolism and AMPK.

Conclusions

miR-15a-5p and miR-17-5p were identified as predictive biomarkers of MetS, irrespective of sexes, further demonstrating the relationship of c-miRNAs to known pathways of metabolic disturbances present in cardio-metabolic diseases.

Available only for authorised users

Paniagua JA (2016) Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes 7:483–514. https://doi.org/10.4239/wjd.v7.i19.483 CrossRefPubMedPubMedCentral

Martyn JAJ, Kaneki M, Yasuhara S (2008) Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 109:137–148. https://doi.org/10.1097/ALN.0b013e3181799d45 CrossRefPubMed

Fernández-Hernando C, Ramírez CM, Goedeke L, Suárez Y (2013) MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 33:178–185. https://doi.org/10.1161/ATVBAHA.112.300144 CrossRefPubMedPubMedCentral

Mehta R, Otgonsuren M, Younoszai Z et al (2016) Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol 3:e000096. https://doi.org/10.1136/bmjgast-2016-000096 CrossRefPubMedPubMedCentral

McGregor RA, Choi MS (2011) microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med 11:304–316CrossRef

Victoria B, Nunez Lopez YO, Masternak MM (2017) MicroRNAs and the metabolic hallmarks of aging. Mol Cell Endocrinol 455:131–147. https://doi.org/10.1016/j.mce.2016.12.021 CrossRefPubMedPubMedCentral

Zhao Y, Song Y, Yao L et al (2017) Circulating microRNAs: promising biomarkers involved in several cancers and other diseases. DNA Cell Biol 36:77–94. https://doi.org/10.1089/dna.2016.3426 CrossRefPubMed

Rome S (2015) Use of miRNAs in biofluids as biomarkers in dietary and lifestyle intervention studies. Genes Nutr 10:33CrossRef

Li M, Zhang J (2015) Circulating microRNAs: potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases. Biomed Res Int 2015:730535PubMedPubMedCentral

10.

Calderari S, Diawara MR, Garaud A, Gauguier D (2017) Biological roles of microRNAs in the control of insulin secretion and action. Physiol Genomics 49(1):1–10CrossRef

11.

Deiuliis JA (2016) MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond) 40:88–101. https://doi.org/10.1038/ijo.2015.170 CrossRef

12.

Párrizas M, Novials A (2016) Circulating microRNAs as biomarkers for metabolic disease. Best Pract Res Clin Endocrinol Metab 30:591–601. https://doi.org/10.1016/j.beem.2016.08.001 CrossRefPubMed

13.

Frost RJA, Olson EN (2011) Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci 108:21075–21080. https://doi.org/10.1073/pnas.1118922109 CrossRefPubMed

14.

Heneghan HM, Miller N, McAnena OJ et al (2011) Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab 96:E846–E850. https://doi.org/10.1210/jc.2010-2701 CrossRefPubMed

15.

Poy MN, Eliasson L, Krutzfeldt J et al (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432:226–230. https://doi.org/10.1038/nature03076 CrossRefPubMed

16.

Wang Y-T, Tsai P-C, Liao Y-C et al (2013) Circulating microRNAs have a sex-specific association with metabolic syndrome. J Biomed Sci 20:72. https://doi.org/10.1186/1423-0127-20-72 CrossRefPubMedPubMedCentral

17.

Sharma S, Eghbali M (2014) Influence of sex differences on microRNA gene regulation in disease. Biol Sex Differ 5:3CrossRef

18.

Cleeman JI, Smith SC, Alberti KGMM et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645. https://doi.org/10.1161/circulationaha.109.192644 CrossRefPubMed

19.

Osei-Yeboah J, Owiredu WKBA, Norgbe GK et al (2017) The prevalence of metabolic syndrome and its components among people with type 2 diabetes in the Ho municipality, Ghana: a cross-sectional study. Int J Chronic Dis 2017:1–8. https://doi.org/10.1155/2017/8765804 CrossRef

20.

D’Souza RF, Markworth JF, Aasen KMM et al (2017) Acute resistance exercise modulates microRNA expression profiles: combined tissue and circulatory targeted analyses. PLoS ONE 12:e0181594. https://doi.org/10.1371/journal.pone.0181594 CrossRefPubMedPubMedCentral

21.

Shah JS, Soon PS, Marsh DJ (2016) Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS ONE 11:e0153200. https://doi.org/10.1371/journal.pone.0153200 CrossRefPubMedPubMedCentral

22.

Zalewski K, Misiek M, Kowalik A et al (2017) Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma. Tumor Biol 39:101042831771714. https://doi.org/10.1177/1010428317717140 CrossRef

23.

Bignotti E, Calza S, Tassi RA et al (2016) Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med 20:2341–2348. https://doi.org/10.1111/jcmm.12927 CrossRefPubMedPubMedCentral

24.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101–1108. https://doi.org/10.1038/nprot.2008.73 CrossRef

25.

Backes C, Kehl T, Stöckel D et al (2017) miRPathDB: a new dictionary on microRNAs and target pathways. Nucl Acids Res 45:D90–D96. https://doi.org/10.1093/nar/gkw926 CrossRefPubMed

26.

Stöckel D, Kehl T, Trampert P et al (2016) Multi-omics enrichment analysis using the GeneTrail2 web service. Bioinformatics 32:1502–1508. https://doi.org/10.1093/bioinformatics/btv770 CrossRefPubMed

27.

Sliwinska A, Kasinska MA, Drzewoski J (2017) MicroRNAs & metabolic disorders—where are we heading? Arch Med Sci 13:885–896. https://doi.org/10.5114/aoms.2017.65229 CrossRefPubMedPubMedCentral

28.

Chen Y, Tian L, Wan S et al (2016) MicroRNA-17-92 cluster regulates pancreatic beta-cell proliferation and adaptation. Mol Cell Endocrinol 437:213–223. https://doi.org/10.1016/j.mce.2016.08.037 CrossRefPubMed

29.

Li H, Li T, Wang S et al (2013) miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Stem Cell Res 10:313–324. https://doi.org/10.1016/j.scr.2012.11.007 CrossRefPubMed

30.

Wang Q, Li YC, Wang J et al (2008) miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci USA 105:2889–2894. https://doi.org/10.1073/pnas.0800178105 CrossRefPubMed

31.

Kamalden TA, Macgregor-Das AM, Kannan SM et al (2017) Exosomal microRNA-15a transfer from the pancreas augments diabetic complications by inducing oxidative stress. Antioxid Redox Signal 27:913–930. https://doi.org/10.1089/ars.2016.6844 CrossRefPubMedPubMedCentral

32.

Martinez-Sanchez A, Rutter GA, Latreille M (2017) miRNAs in β-cell development, identity, and disease. Front Genet 7:226. https://doi.org/10.3389/fgene.2016.00226 CrossRefPubMedPubMedCentral

33.

Sun L-L, Jiang B-G, Li W-T et al (2011) MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 91:94–100. https://doi.org/10.1016/j.diabres.2010.11.006 CrossRefPubMed

34.

Rawal S, Munasinghe PE, Nagesh PT et al (2017) Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type 2 diabetic human and mouse heart. Clin Sci 131:847–863. https://doi.org/10.1042/CS20160916 CrossRefPubMed

35.

Guo L, Zhang Q, Ma X et al (2017) miRNA and mRNA expression analysis reveals potential sex-biased miRNA expression. Nature 7:39812. https://doi.org/10.1038/srep39812 CrossRef

36.

Pérez-Cremades D, Mompeón A, Gómez XV et al (2018) MiRNA as a new regulatory mechanism of estrogen vascular action. Int J Mol Sci 19:473CrossRef

37.

Ameling S, Kacprowski T, Chilukoti RK et al (2015) Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study. BMC Med Genomics 8:61. https://doi.org/10.1186/s12920-015-0136-7 CrossRefPubMedPubMedCentral

38.

Wang H, Peng R, Wang J et al (2018) Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenet 10:59CrossRef

39.

Sun T, Fu M, Bookout AL et al (2009) MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol Endocrinol 23:925–931. https://doi.org/10.1210/me.2008-0298 CrossRefPubMedPubMedCentral

40.

Jones A, Danielson KM, Benton MC et al (2017) miRNA signatures of insulin resistance in obesity. Obesity 25:1734–1744. https://doi.org/10.1002/oby.21950 CrossRefPubMed

41.

Burgess KS, Philips S, Benson EA et al (2015) Age-related changes in microRNA expression and pharmacogenes in human liver. Clin Pharmacol Ther 98:205–215. https://doi.org/10.1002/cpt.145 CrossRefPubMedPubMedCentral

42.

Noren Hooten N, Abdelmohsen K, Gorospe M et al (2010) microRNA expression patterns reveal differential expression of target genes with age. PLoS ONE 5:e10724. https://doi.org/10.1371/journal.pone.0010724 CrossRefPubMedPubMedCentral

43.

Dluzen DF, Noren Hooten N, Zhang Y et al (2016) Racial differences in microRNA and gene expression in hypertensive women. Sci Rep 6:35815. https://doi.org/10.1038/srep35815 CrossRefPubMedPubMedCentral

44.

Huang RS, Gamazon ER, Ziliak D et al (2011) Population differences in microRNA expression and biological implications. RNA Biol 8:692–701. https://doi.org/10.4161/rna.8.4.16029 CrossRefPubMedPubMedCentral

Title: Circulatory miRNA biomarkers of metabolic syndrome
Authors: F. Ramzan
R. F. D’Souza
B. R. Durainayagam
A. M. Milan
J. F. Markworth
V. Miranda-Soberanis
I. R. Sequeira
N. C. Roy
S. D. Poppitt
C. J. Mitchell
D. Cameron-Smith
Publication date: 01-02-2020
Publisher: Springer Milan
Keywords: Insulins
Insulins
Biomarkers
Published in: Acta Diabetologica / Issue 2/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01406-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Deficiency of glutathione peroxidase-1 and catalase attenuated diet-induced obesity and associated metabolic disorders

Correction to: The ZJU index is a powerful index for identifying NAFLD in the general Chinese population

Impact of lifetime marijuana use on fasting plasma insulin levels and HOMA-IR score in obese adults with and without insulin resistance

Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries

The analytical performance of laboratory plasma glucose and HbA1c measurements are largely acceptable

Diabetic retinopathy screening using a virtual reading center

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials